Traders should view this as a positive de-risking event that enhances izicopan's commercial potential, particularly for combination therapies requiring concomitant medications like corticosteroids. The improved safety profile may increase partnering interest or support future premium pricing, especially in chronic indications.
Price Chart
Executive Summary
InflaRx announced new in vitro data showing izicopan does not exhibit time-dependent inhibition of CYP3A4, a key enzyme linked to drug-drug interactions and liver toxicity, reinforcing its favorable safety and pharmacological profile. This supports izicopan’s potential as a best-in-class oral C5aR inhibitor with low risk of clinically relevant drug interactions.
Key Facts
- New Ki-based TDI study confirms izicopan does not inhibit CYP3A4 (IC₅₀ > 100 µM) and shows no time-dependent inhibition up to 100 µM.
- Results support low risk of clinically relevant drug-drug interactions (DDIs) and hepatotoxicity.
- Izicopan previously demonstrated strong safety in Phase 1 and Phase 2a trials across multiple inflammatory diseases including hidradenitis suppurativa and chronic spontaneous urticaria.
- Differentiation from existing C5aR inhibitors due to lack of CYP3A4 inhibition is highlighted as a key advantage.
Financial Impact
Non-financial but material to valuation — strengthens clinical differentiation and de-risking of development pathway.
Risk Factors
- Forward-looking statements are subject to regulatory and clinical trial risks.
- Market cap remains small ($69M), making the stock volatile and sensitive to future data readouts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270828 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.58 (+0.96%) |
Oct 22, 2026 4d ago | Press Release | $1.53 | awaiting T+20 | — | $1.58 (+2.94%) |
Oct 2, 2026 24d ago | Press Release | $1.72 | awaiting T+20 | — | $1.58 (−8.43%) |
Oct 1, 2026 25d ago | Press Release | $1.71 | awaiting T+20 | — | $1.58 (−7.89%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.58 (+23.91%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.58 (+21.64%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.58 (−8.43%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.58 (−32.40%) |
Jun 30, 2026 16w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.58 (−29.69%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.58 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers